Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IDE-161 by Ideaya Biosciences for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Risk adjusted net present value: What is the current valuation of Ideaya Biosciences's IDE-161?
IDE-161 is a small molecule commercialized by Ideaya Biosciences, with a leading Phase II program in Metastatic Ovarian Cancer. According...
IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData,...
IDE-161 by Ideaya Biosciences for Colon Cancer: Likelihood of Approval
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Colon Cancer. According to GlobalData, Phase...
IDE-161 by Ideaya Biosciences for Endometrial Cancer: Likelihood of Approval
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
IDE-161 by Ideaya Biosciences for Prostate Cancer: Likelihood of Approval
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
IDE-161 by Ideaya Biosciences for Gastric Cancer: Likelihood of Approval
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
IDE-161 by Ideaya Biosciences for Colorectal Cancer: Likelihood of Approval
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...